BA Chemistry - Orthofix Medical Chief Officer
| OFIX Stock | USD 19.34 0.30 1.58% |
Insider
BA Chemistry is Chief Officer of Orthofix Medical
| Age | 63 |
| Address | 3451 Plano Parkway, Lewisville, TX, United States, 75056 |
| Phone | 214 937 2000 |
| Web | https://www.orthofix.com |
Orthofix Medical Management Efficiency
The company has return on total asset (ROA) of (0.0237) % which means that it has lost $0.0237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2086) %, meaning that it created substantial loss on money invested by shareholders. Orthofix Medical's management efficiency ratios could be used to measure how well Orthofix Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.23 in 2024. Return On Capital Employed is likely to rise to -0.17 in 2024. At this time, Orthofix Medical's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 530.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 21.1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rebecca Kuhn | Neuropace | 63 | |
| Margaret Carthy | Integer Holdings Corp | 60 | |
| Leana Wen | Glaukos Corp | 37 | |
| Stacie Rodgers | Sight Sciences | N/A | |
| David MD | Sight Sciences | 54 | |
| Martha Morrell | Neuropace | 67 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Mark Saxton | Neuropace | 59 | |
| Mory Gharib | Glaukos Corp | N/A | |
| Andre Marquette | Neuropace | N/A | |
| Michael Favet | Neuropace | 54 | |
| Steve Deitsch | Paragon 28 | N/A | |
| Collin DSilva | Bruker | 67 | |
| B Johnson | Paragon 28 | 68 | |
| Meghan Scanlon | Paragon 28 | 48 | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| David Haffner | Glaukos Corp | N/A | |
| Richard Holifield | Globus Medical | N/A | |
| Kelly Huller | Globus Medical | 48 | |
| Laverne Council | CONMED | 59 | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.0237 |
Orthofix Medical Leadership Team
Elected by the shareholders, the Orthofix Medical's board of directors comprises two types of representatives: Orthofix Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orthofix. The board's role is to monitor Orthofix Medical's management team and ensure that shareholders' interests are well served. Orthofix Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orthofix Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA Chemistry, Chief Officer | ||
| Kimberley Elting, President Orthopedics | ||
| Julie Dewey, Chief Officer | ||
| Andres Cedron, Chief Secretary | ||
| Stephanie Walsh, Chief Officer | ||
| Ehab Esmail, Regulatory Quality | ||
| Lucas Vitale, Chief Officer | ||
| Aviva McPherron, President Quality | ||
| Suzanne Armstrong, Chief Officer | ||
| Douglas Rice, CFO Officer | ||
| Jon Serbousek, President - Global Spine Business | ||
| Frank Vizesi, Chief Officer | ||
| Jill Mason, Interim Counsel | ||
| Geoffrey Gillespie, VP Controller | ||
| Julie Andrews, Chief Officer | ||
| Roberto Donadello, Senior Operations | ||
| Mark Quick, Sr Relations | ||
| Tyler Lipschultz, President Biologics | ||
| Kevin Kenny, President Business | ||
| Dan Yarbrough, Vice Relations | ||
| Massimo Calafiore, CEO, President |
Orthofix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orthofix Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.0237 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 838.22 M | ||||
| Shares Outstanding | 38.21 M | ||||
| Shares Owned By Insiders | 4.99 % | ||||
| Shares Owned By Institutions | 92.32 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Earning | 338.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Orthofix Stock Analysis
When running Orthofix Medical's price analysis, check to measure Orthofix Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orthofix Medical is operating at the current time. Most of Orthofix Medical's value examination focuses on studying past and present price action to predict the probability of Orthofix Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orthofix Medical's price. Additionally, you may evaluate how the addition of Orthofix Medical to your portfolios can decrease your overall portfolio volatility.